{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T19:22:42Z","timestamp":1771615362041,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,5,25]],"date-time":"2017-05-25T00:00:00Z","timestamp":1495670400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1055176"],"award-info":[{"award-number":["1055176"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1061041"],"award-info":[{"award-number":["1061041"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1002611"],"award-info":[{"award-number":["1002611"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Med. Toxicol."],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s13181-017-0615-7","type":"journal-article","created":{"date-parts":[[2017,5,25]],"date-time":"2017-05-25T14:44:33Z","timestamp":1495723473000},"page":"343-346","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Pramipexole Overdose Associated with Visual Hallucinations, Agitation and Myoclonus"],"prefix":"10.1007","volume":"13","author":[{"given":"Adeline","family":"Cardon-Dunbar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael S.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1519-7419","authenticated-orcid":false,"given":"Geoffrey K.","family":"Isbister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,5,25]]},"reference":[{"issue":"3","key":"615_CR1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017723","volume":"6","author":"K Ishibashi","year":"2011","unstructured":"Ishibashi K, Ishii K, Oda K, Mizusawa H, Ishiwata K. Binding of pramipexole to extrastriatal dopamine D2\/D3 receptors in the human brain: a positron emission tomography study using 11C-FLB 457. PLoS One. 2011;6(3):e17723.","journal-title":"PLoS One"},{"key":"615_CR2","first-page":"417","volume":"12","author":"S Biase de","year":"2016","unstructured":"de Biase S, Valente M, Gigli GL. Intractable restless legs syndrome: role of prolonged-release oxycodone-naloxone. Neuropsychiatr Dis Treat. 2016;12:417\u201325.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"18","key":"615_CR3","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1007\/s40265-014-0322-5","volume":"74","author":"JE Frampton","year":"2014","unstructured":"Frampton JE. Pramipexole extended-release: a review of its use in patients with Parkinson\u2019s disease. Drugs. 2014;74(18):2175\u201390.","journal-title":"Drugs"},{"issue":"6","key":"615_CR4","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1212\/01.wnl.0000231513.23919.a1","volume":"67","author":"JW Winkelman","year":"2006","unstructured":"Winkelman JW, Sethi KD, Kushida CA, Becker PM, Koester J, Cappola JJ, et al. Efficacy and safety of pramipexole in restless legs syndrome. Neurology. 2006;67(6):1034\u20139.","journal-title":"Neurology"},{"issue":"2","key":"615_CR5","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/01.wnf.0000240943.59617.4c","volume":"30","author":"Parkinson Study G","year":"2007","unstructured":"Parkinson Study G. Pramipexole in levodopa-treated Parkinson disease patients of African, Asian, and Hispanic heritage. Clin Neuropharmacol. 2007;30(2):72\u201385.","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"615_CR6","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2147\/NDT.S2325","volume":"4","author":"R Constantinescu","year":"2008","unstructured":"Constantinescu R. Update on the use of pramipexole in the treatment of Parkinson\u2019s disease. Neuropsychiatr Dis Treat. 2008;4(2):337\u201352.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"9","key":"615_CR7","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/qjmed\/hcg109","volume":"96","author":"EJ Dunkley","year":"2003","unstructured":"Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635\u201342.","journal-title":"QJM"},{"key":"615_CR8","unstructured":"Chunduri RHB, Dannana GS, Chodae SB, Koppula KC, Deta SI, Konduru B. UPLC-MS\/MS method for simultaneous quantification of pramipexole, ropinirole and rasagiline in human plasma and its application to a pharmacokinetic study. Am J PharmTech Res. 2013;3(3)."},{"key":"615_CR9","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jchromb.2016.02.041","volume":"1017-1018","author":"S Mohamed","year":"2016","unstructured":"Mohamed S, Riva R, Contin M. Validated UHPLC-MS\/MS method for the simultaneous determination of pramipexole and ropinirole in plasma of patients with Parkinson\u2019s disease. J Chromatogr B Anal Technol Biomed Life Sci. 2016;1017-1018:114\u20139.","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"issue":"7","key":"615_CR10","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1007\/s00216-010-3485-2","volume":"396","author":"S Dresen","year":"2010","unstructured":"Dresen S, Ferreiros N, Gnann H, Zimmermann R, Weinmann W. Detection and identification of 700 drugs by multi-target screening with a 3200 Q TRAP LC-MS\/MS system and library searching. Anal Bioanal Chem. 2010;396(7):2425\u201334.","journal-title":"Anal Bioanal Chem"},{"issue":"7","key":"615_CR11","first-page":"447","volume":"58","author":"M Schulz","year":"2003","unstructured":"Schulz M, Schmoldt A. Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics. Pharmazie. 2003;58(7):447\u201374.","journal-title":"Pharmazie"},{"issue":"27","key":"615_CR12","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000000251","volume":"93","author":"H Kataoka","year":"2014","unstructured":"Kataoka H, Ueno S. Auditory musical hallucinations associated with extended-release pramipexole in an elderly patient with Parkinson\u2019s disease. Medicine (Baltimore). 2014;93(27):e251.","journal-title":"Medicine (Baltimore)"},{"key":"615_CR13","doi-asserted-by":"crossref","unstructured":"Signorelli MS, Battaglia E, Costanzo MC, Cannavo D. Pramipexole induced psychosis in a patient with restless legs syndrome. BMJ Case Rep. 2013;2013.","DOI":"10.1136\/bcr-2013-009716"},{"issue":"1","key":"615_CR14","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3109\/15563650.2013.859264","volume":"52","author":"I Berling","year":"2014","unstructured":"Berling I, Isbister GK. Mirtazapine overdose is unlikely to cause major toxicity. Clin Toxicol (Phila). 2014;52(1):20\u20134.","journal-title":"Clin Toxicol (Phila)"},{"issue":"1","key":"615_CR15","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/15563650601005837","volume":"45","author":"WS Waring","year":"2007","unstructured":"Waring WS, Good AM, Bateman DN. Lack of significant toxicity after mirtazapine overdose: a five-year review of cases admitted to a regional toxicology unit. Clin Toxicol (Phila). 2007;45(1):45\u201350.","journal-title":"Clin Toxicol (Phila)"},{"issue":"5","key":"615_CR16","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/qjmed\/hcg062","volume":"96","author":"IM Whyte","year":"2003","unstructured":"Whyte IM, Dawson AH, Buckley NA. Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. QJM. 2003;96(5):369\u201374.","journal-title":"QJM"},{"issue":"7","key":"615_CR17","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1081\/CLT-100102530","volume":"37","author":"JB Hack","year":"1999","unstructured":"Hack JB, Powell G, Nelson LS, Hoffman RS, Howland MA. Acute pediatric exposure to pramipexole dihydrochloride (Mirapex (R) ). J Toxicol Clin Toxicol. 1999;37(7):891\u20132.","journal-title":"J Toxicol Clin Toxicol"},{"key":"615_CR18","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2147\/NDT.S49454","volume":"9","author":"W Zhang","year":"2013","unstructured":"Zhang W, Wang Y, Cong SY, Nao JF, Feng J, Bi GR. Efficacy and tolerability of pramipexole for the treatment of primary restless leg syndrome: a meta-analysis of randomized placebo-controlled trials. Neuropsychiatr Dis Treat. 2013;9:1035\u201343.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"10","key":"615_CR19","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1517\/17425255.2011.614232","volume":"7","author":"A Antonini","year":"2011","unstructured":"Antonini A, Calandrella D. Pharmacokinetic evaluation of pramipexole. Expert Opin Drug Metab Toxicol. 2011;7(10):1307\u201314.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"6","key":"615_CR20","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/j.1552-4604.1997.tb04330.x","volume":"37","author":"CE Wright","year":"1997","unstructured":"Wright CE, Sisson TL, Ichhpurani AK, Peters GR. Steady-state pharmacokinetic properties of pramipexole in healthy volunteers. J Clin Pharmacol. 1997;37(6):520\u20135.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"615_CR21","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1590\/S0004-282X2008000600025","volume":"66","author":"LA Dutra","year":"2008","unstructured":"Dutra LA, Pedroso JL, Felix EP, Barsottini OG. Venlafaxine induced-myoclonus in a patient with mixed dementia. Arq Neuropsiquiatr. 2008;66(4):894\u20135.","journal-title":"Arq Neuropsiquiatr"},{"issue":"4","key":"615_CR22","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/00004714-200108000-00020","volume":"21","author":"I Anghelescu","year":"2001","unstructured":"Anghelescu I, Klawe C, Himmerich H, Szegedi A. Topiramate in venlafaxine-induced visual hallucinations in an obese patient with a posterior cerebral artery infarction. J Clin Psychopharmacol. 2001;21(4):462\u20134.","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"615_CR23","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1017\/S1041610210000554","volume":"22","author":"KP Padala","year":"2010","unstructured":"Padala KP, Padala PR, Malloy T, Burke WJ. New onset multimodal hallucinations associated with mirtazapine: a case report. Int Psychogeriatr. 2010;22(5):837\u20139.","journal-title":"Int Psychogeriatr"},{"issue":"1","key":"615_CR24","doi-asserted-by":"crossref","first-page":"79","DOI":"10.5664\/jcsm.27716","volume":"6","author":"R Hoque","year":"2010","unstructured":"Hoque R, Chesson AL Jr. Pharmacologically induced\/exacerbated restless legs syndrome, periodic limb movements of sleep, and REM behavior disorder\/REM sleep without atonia: literature review, qualitative scoring, and comparative analysis. J Clin Sleep Med. 2010;6(1):79\u201383.","journal-title":"J Clin Sleep Med"},{"issue":"5","key":"615_CR25","doi-asserted-by":"crossref","first-page":"661","DOI":"10.5665\/sleep.2622","volume":"36","author":"S Fulda","year":"2013","unstructured":"Fulda S, Kloiber S, Dose T, Lucae S, Holsboer F, Schaaf L, et al. Mirtazapine provokes periodic leg movements during sleep in young healthy men. Sleep. 2013;36(5):661\u20139.","journal-title":"Sleep"}],"container-title":["Journal of Medical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13181-017-0615-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13181-017-0615-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13181-017-0615-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T14:10:06Z","timestamp":1602166206000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13181-017-0615-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,25]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["615"],"URL":"https:\/\/doi.org\/10.1007\/s13181-017-0615-7","relation":{},"ISSN":["1556-9039","1937-6995"],"issn-type":[{"value":"1556-9039","type":"print"},{"value":"1937-6995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,25]]}}}